Literature DB >> 27393301

Clinical vertebral fractures following denosumab discontinuation.

Stergios A Polyzos1, Evangelos Terpos2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27393301     DOI: 10.1007/s12020-016-1030-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  3 in total

1.  Multiple clinical vertebral fractures following denosumab discontinuation.

Authors:  A D Anastasilakis; P Makras
Journal:  Osteoporos Int       Date:  2015-12-22       Impact factor: 4.507

2.  Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.

Authors:  B Aubry-Rozier; E Gonzalez-Rodriguez; D Stoll; O Lamy
Journal:  Osteoporos Int       Date:  2015-10-28       Impact factor: 4.507

3.  Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.

Authors:  A W Popp; P K Zysset; K Lippuner
Journal:  Osteoporos Int       Date:  2015-12-22       Impact factor: 4.507

  3 in total
  4 in total

Review 1.  Denosumab: an Emerging Therapy in Pediatric Bone Disorders.

Authors:  Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

2.  Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.

Authors:  N Binkley; D Krueger; A E de Papp
Journal:  Osteoporos Int       Date:  2018-02-18       Impact factor: 4.507

3.  Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.

Authors:  M B Zanchetta; J Boailchuk; F Massari; F Silveira; C Bogado; J R Zanchetta
Journal:  Osteoporos Int       Date:  2017-10-03       Impact factor: 4.507

Review 4.  Advances and Unmet Needs in the Therapeutics of Bone Fragility.

Authors:  Sabashini K Ramchand; Ego Seeman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-06       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.